Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Growth of In-Situ Hybridization Testing Exceeds Other Technologies

By LabMedica International staff writers
Posted on 26 Apr 2010
In situ hybridization tests (ISH), which are probes for specific DNA sequences performed on portions of tumor tissue, have become one of the fastest growing market segments in laboratory medicine, showing 8% sales growth per year, according to a recent market report. More...


With new enhancements the technology will continue to drive revenues for Abbott Laboratories (Abbott Park, IL, USA), Genzyme (Cambridge, MA, USA), Nitrogen (Carlsbad, CA, USA), and a host of other test makers, according to a report from healthcare market research publisher Kalorama Information (New York, NY, USA). The report noted that ISH has performed better than other technologies that were predicted to dominate the industry.

"ISH is carving out a growing market share because of its usefulness for a variety of cancer markers including ER [estrogen receptor], PSA [prostate-specific antigen], EGFR [epidermal growth factor receptor], and Her-2 [human epidermal growth factor receptor 2],” said Shara Rosen, senior diagnostic analyst for Kalorama Information. "It has outperformed expectations made for it in the last decade and shown more growth so far than other celebrated areas such as microarrays and DNA assays.”

The world market for all ISH (silver, chromomeric, or fluorescent) is estimated by Kalorama Information to be US$670 million in 2009. Vendor sales are comprised mostly of individual antibodies or probes and instrumentation to automate the staining and reading of slides, along with digital imaging systems and data analysis software in high-end systems. It is these systems, which offer automated sample preparation and digital analysis instrumentation that Kalorama Information believes will continue to put ISH in a leadership position, allowing for same-day biopsy results and better patient care.

"The technology is moving from manual and operator-read to automated and digitally interpreted,” said Ms. Rosen. "ISH testing used to be qualitative and inherently subjective; resulting in significant deficiencies in the interpretation of test results, but automation has made it more relevant.”

The new automation has also allowed some movement of histology from hospital and reference laboratories to large physician practices in the United States. Digital imaging can convert entire microscope slides into high-resolution digital slides. Therefore, digitized images of an entire slide can be analyzed, stored, and remotely viewed on computer monitors located anywhere. This digital capability sets the stage for pathology telemedicine and small bench top systems for small labs and physician office laboratories as well as labs in rural areas, according to Kalorama.

Related Links:

Kalorama Information



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.